Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Exotic & Emerging Avian Viral Diseases Research » Research » Publications at this Location » Publication #209343

Title: Future of vaccines for the poultry industry

item Suarez, David

Submitted to: American Association of Avian Pathologists
Publication Type: Abstract Only
Publication Acceptance Date: 4/15/2007
Publication Date: 7/15/2007
Citation: Suarez, D.L. 2007. Future of vaccines for the poultry industry [abstract]. In: Proceedings of the American Association of Avian Pathologists Symposium, Biotechnology--Impact on Poultry Health, July 15, 2007, Washington, DC. p. 48-52.

Interpretive Summary:

Technical Abstract: The role of biotechnology to develop new and innovative vaccines for both veterinary and human health has been slower than most scientists would have predicted 10 years ago. The issues with poultry have been both regulatory and economic. For example, the viral vectored vaccines have higher regulatory hurtles that require longer and more costly licensure requirements. In addition the new technology often has higher costs associated with patents and investment in new technology that has made it difficult to compete on cost with existing technologies even when the new vaccines have distinctive advantages. The trend however is positive for the continued licensing of new technologies. The use virus vectored vaccines will continue to grow in importance, although safety and vaccine spread will remain issues particularly in some parts of the world. For safety concerns, the use of replication restricted viruses will provide benefits to the industry if it can be produced in a cost effective manner. Vectors that can spread laterally may be valuable for mass vaccination, but they are likely to face stiff regulatory scrutiny. Alternative technologies such as plant based protein expression systems may provide unique advantages. The goal of feed based vaccines however are still far from fruition. Our understanding of the innate immune response and how to target different immunological pathways are likely going to open up the area of adjuvants. The understanding of how to target the immune response to improve either antibody or cell mediated immune response will likely provide better vaccine protection with fewer side effects of vaccination. Biotechnologies impact on vaccine will continue to blossom as we improve our understanding the benefits and risks of the technology.